Advertisement

Topics

Novartis Back In AMD Game With ‘Potential Blockbuster’ Brolucizumab

08:09 EST 12 Nov 2017 | SCRIP

Novartis says nAMD eye treatment brolucizumab showed further advantages over Eylea in two Phase III studies, reinforcing plans to file...

      

Related Stories

 

Original Article: Novartis Back In AMD Game With ‘Potential Blockbuster’ Brolucizumab

NEXT ARTICLE

More From BioPortfolio on "Novartis Back In AMD Game With ‘Potential Blockbuster’ Brolucizumab"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topics

The Top 100 Pharmaceutical Companies
Top 10 biotech and pharmaceutical companies worldwide based on market value in 2015 2015 ranking of the global top 10 biotech and pharmaceutical companies based on revenue (in billion U.S. dollars) Johnson & Johnson, U.S. 74...

Clincial Trials
In a clinical trial or interventional study, participants receive specific interventions according to the research plan or protocol created by the investigators. These interventions may be medical products, such as drugs or devices; procedures; or change...